Introduction
It has been established that the histamine H2-receptor antagonist, cimetidine, promotes healing of duodenal ulcers (Bodemar and Walan, 1976; Blackwood et al., 1976; Haggie, Fumont and Wyllie, 1976) . The role of cimetidine in the treatment of gastric ulceration is less clear, although healing does occur in 60 to 80% of cases with a 4-or 6-week course of treatment (Ciclitira et al., 1977; Multicentre Trial, 1977; Frost et al., 1977; Dyck et al., 1978) . The high incidence of subsequent recurrence, however, remains a major problem in the long-term medical management of both gastric and duodenal ulcers (Leading Article, 1977) . Recent studies (Gray et al., 1978; Blackwood, Maudgal and Northfield, 1978) 
Patients and methods
Patients with endoscopically-proved benign gastric ulcers were initially treated with cimetidine or placebo in a 4-week trial. The protocol of this trial has previously been published (Ciclitira et al., 1977 The timing of relapse is shown in Fig. 1 Return tablet counts demonstrated that both patients on cimetidine who relapsed had omitted to take the correct number of tablets.
Nine out of 11 patients on cimetidine remained free from ulcer pain during the trial as compared to 5 out of 14 patients on placebo (P <0-05). Cimetidinetreated patients consumed less antacid tablets throughout the trial than those treated with placebo, although the difference was not significant.
Discussion
This study, over 11 months, demonstrates that cimetidine 1 g daily significantly reduces the incidence of gastric ulcer relapse.
Twenty-two of the 25 patients who completed the study had originally healed their gastric ulcer with cimetidine before entry into this trial. Of the 3 patients whose ulcers originally healed on placebo, 2 remained healed on maintenance cimetidine and one patient relapsed on cimetidine. The risk of relapse appeared unrelated to whether the original ulcer had healed on cimetidine or placebo tablets.
In this maintenance trial the high rate of ulcer recurrence in the placebo-treated group (12 of 14 patients) suggests that the majority of patients will have recurrent gastric ulcers within 6 months of the initial healing. This is similar to the experience with cimetidine in duodenal ulceration (Haggie et al., 1976; Blackwood et al., 1978) .
This study included a single patient with a prepyloric ulcer, which remained healed on cimetidine. As ulcers at this site are often, like duodenal ulcers, associated with increased gastric acid secretion, it can be argued that cimetidine might be expected to be more effective in preventing relapse of this type of ulcer. If this patient is excluded from the analysis the results remain highly significant (P=0-002).
In the United Kingdom, gastric ulceration is principally a disease of the elderly and the morbidity and mortality associated with complications such as haemorrhage is high. In many such patients, particularly those with intercurrent disease, ulcer surgery is also associated with significant risk (Allan and Dykes, 1976 ).
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Maintenance treatment with cimetidine offers a safe and effective alternative to surgery in the prevention of gastric ulcer relapse and would appear to have an important role in this disease. There is, however, no evidence that prolonged treatment will alter the ulcer diathesis.
It remains to be seen whether a lower dose of cimetidine will also prove effective in preventing gastric ulcer recurrence.
